MYO7A

Across TCGA pan-cancer cohorts, MYO7A RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of MYO7A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MYO7A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MYO7A is over-expressed in tumor, although a few such as BRCA and KICH show the opposite, repressed pattern.

HNSC, KIRC, and COAD are the cancer types where MYO7A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYO7A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+1.001	<.001	12	view →
KIRC	Female	All	+1.311	<.001	11	view →
COAD	Female	All	+0.958	<.001	10	view →
LUAD	Male	All	+1.402	<.001	9	view →
STAD	Male	III,IV	+1.888	<.001	8	view →
LUSC	Female	All	+0.815	<.001	7	view →
BRCA	All	III,IV	−0.674	<.001	6	view →
ESCA	All	All	+1.107	.009	5	view →
THCA	Female	II,III,IV	+0.682	.008	5	view →
KICH	All	II,III,IV	−0.634	.021	3	view →
READ	Female	All	+0.933	.003	2	view →
KIRP	All	III,IV	−0.821	.017	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

MYO7A–HNSC

Open the HNSC breakdown →